Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer

BETHLEHEM, Pa., Nov. 16, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Mark D. Myslinski has been appointed senior vice president and chief commercial officer of the company.

Mr. Myslinski has nearly 30 years of life sciences and diagnostics industry experience with Fortune 100 and venture-backed startup organizations.  He was recently president and CEO of RedPath Integrated Pathology, Inc. where he and the team transformed the company from a research and market development focus to full commercialization of a novel molecular diagnostic assay in a Clinical Laboratory Improvements Amendments (CLIA) certified laboratory.

"Mark's extensive experience in diagnostics and his leadership within the life science community will be invaluable to Saladax as the company targets new markets for the commercialization of its MyCare assays," said Kevin Harter, president and CEO of Saladax.  "In particular, Mark's expertise will be critical as Saladax pursues the formation of a laboratory that meets CLIA standards."

Previous to Mr. Myslinski's time at RedPath Integrated Pathology, Inc., he served as vice president of evidence-based medicine at Ortho Clinical Diagnostics, Inc. and general manager, molecular and cellular diagnostics division of Veridex, LLC, both of which are Johnson & Johnson companies.

"I'm excited to join Saladax during this time of rapid growth with the formation of a CLIA certified laboratory at the company's headquarters and the continued expansion of its MyCare assays worldwide," said Mr. Myslinski.  "Saladax's solutions offer patients a means of personalized chemotherapy treatment by finding the optimal dose for each individual patient. This is very important to clinical outcomes by assuring the right dosage gets delivered to the patient in the most efficient manner."

About Saladax Biomedical, Inc.
Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine.  Our proprietary line of MyCare™ assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient.  Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development.  Three MyCare assays, My5-FU™, MyPaclitaxel™ and MyDocetaxel™, are currently offered to the oncology community in markets around the world. 

The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories.  This technology also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania.  Saladax is ISO 13485:2003 certified.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
Sr. VP & Chief Operating Officer
[email protected]

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
[email protected]
or
Claire Sojda
[email protected]

SOURCE Saladax Biomedical, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED